News

May 22, 2012 — New long-term data from the DIVERGE study presented at EuroPCR 2012 showed that the use of the Axxess...

May 15, 2012 –– As EuroPCR 2012 gets underway, Medtronic Inc.announced that the Resolute Integrity Coronary Stent System has received European regulatory approval for several new indications...

April 12, 2012 – Abbott announced approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the next-generation Xience Prime Everolimus-Eluting Coronary Stent System for the...

April 6, 2012 — Boston Scientific Corp. announced results from a quantitative coronary angiographic (QCA) analysis of the incidence of longitudinal stent deformation in the PERSEUS and PLATINUM...

Boston Scientific announced its support of the HORIZONS II AMI clinical trial, which is designed to evaluate the safety and efficacy of the Promus Element Plus everolimus-eluting platinum chromium...

Two-year follow-up data from the pivotal PLATINUM Workhorse trial comparing the safety and effectiveness of the Promus Element and Xience V everolimus-eluting coronary stents demonstrated superior...

March 29, 2012 — In the second year of an ongoing trial, the Resolute zotarolimus-eluting stent (Medtronic) achieved a low rate of stent thrombosis, cardiac death, target vessel heart attack and...

Biodegradable polymer drug-eluting stents (DES) provide better long-term safety and efficacy than durable polymer DES, according to findings from an analysis of three major clinical trials — ISAR-...

March 9, 2012 — Boston Scientific Corp. announced the launch of the Promus Element everolimus-eluting coronary stent system in Japan. The product was recently approved by the Ministry of Health,...

March 6, 2012 — In a development that brings advanced combination therapy treatment of peripheral artery disease (PAD) to Japanese patients for the first time, Cook Medical has received PMDA...

The U.S. Food and Drug Administration (FDA) granted the first coronary stent indication for use in patients experiencing an acute myocardial infarction (AMI), or heart attack. The Boston...

February 20, 2012 —Medtronic announced U.S. Food and Drug Administration (FDA) approval of the Resolute Integrity drug-eluting stent (DES)...

February 1, 2012 — Boston Scientific announced the first patient use and European market launch of the Promus Element Plus everolimus-eluting coronary stent system. The first patient implant in...

January 23, 2012 – Boston Scientific Corp. said the U.S. District Court for the District of New Jersey has found all the asserted patents for a coronary stent in a lawsuit brought by Johnson...

January 9, 2012 – A registry that includes every patient in Sweden having percutaneous coronary intervention (PCI) found use of newer generation drug-eluting stents (DES) is associated with lower...

Abbott announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe evaluating the safety and performance of the novel Esprit drug-eluting bioresorbable vascular scaffold (...

Boston Scientific recently announced U.S. Food and Drug Administration (FDA) approval for the Promus Element Plus everolimus-eluting platinum chromium coronary stent system, the company's next-...

December 9, 2011 — Abbott announced Thursday the initiation of ABSORB II, the first randomized, controlled, multi-center clinical trial evaluating the safety, efficacy and performance of the...

November 21, 2011 — Micell Technologies Inc. announced the release of preliminary data from the first-in-human clinical study of the MiStent Sirolimus Drug Eluting Coronary Stent System (MiStent...

November 15, 2011 – The risk of late stent thrombosis (ST) in the first generation of drug-eluting stents continues for up to seven years after implantation, and certain...